Adeno Associated Virus (AAV) Vector Manufacturing Market Size to Reach USD 4,829.1 Million in 2032
The Adeno Associated Virus (AAV) Vector Manufacturing Market size was USD 1,148.4 Million in 2024 and is expected to register a revenue CAGR of 19.6% during the forecast period.
04 February, 2025 – Technological advancements in AAV manufacturing is a key factor driving market revenue growth. The demand for affordable vector manufacturing technologies and viral vector production platforms for human gene therapy products has increased due to the popularity of adeno-associated viruses and the growing interest in gene therapies. The incorporation of single-use technologies has become critical in both upstream and downstream processing, providing increased efficiency, flexibility, and cost effectiveness. Single-use bioreactors and fermenters enable scalable cultivation and vector generation by eliminating the need for time-consuming cleaning between batches.
On March 2024, ReciBioPharm, Recipharm’s advanced and emerging therapies business unit, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance the development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, which will be the first to treat haemophilia patients with inhibitors. ReciBioPharm and GeneVentiv’s collaboration will assist address the present unmet need for AAV-based gene treatments for haemophilia patients with inhibitors.
However, Adeno-associated viruses (AAV) manufacturing poses several issues. Preclinical research efforts can be delayed due to high wait periods at commercial production facilities. Furthermore, scalability can be a challenge, as increasing AAV production to meet high-demand requirements frequently finds technical and logistical constraints. This creates a significant barrier to widespread commercialization and clinical applications.
Key Highlights:
- Chromatography segment is expected to register the highest growth rate over the forecast period. Chromatographic resins feature a unique surface chemistry that selectively binds AAVs based on their size, charge, or affinity for certain ligands. AAVs are passed via a resin-packed column. Contaminants with weak interactions pass through the column first, while AAVs bind to the resin. Subsequent elution processes using appropriate buffers or solutions separate the AAVs from the resin, resulting in their purification.
- Gene therapy segment is expected to account for the largest revenue share over the forecast period. Adeno-associated virus (AAV) vectors have emerged as an exciting method for gene therapy, with enormous promise to treat a wide range of genetic problems. Adeno-associated viral (AAV) vectors are a typical gene therapy delivery technology that offers several advantages over other vectors, including increased safety. Furthermore, the simplicity of their genomic structure makes manipulating experiments easier. They differ in their selection of target cells (tropism) due to the distinct surface structures of their envelope proteins. There are very few cell types that would not be able to receive AAV vector DNA since a vector genome may be readily packaged in the envelope of any AAV serotype. Because of their adaptability and inherent simplicity, AAVs have proven to be a useful tool in the development of gene treatments.
- North America accounted for the largest revenue share in the Adeno Associated Virus (AAV) Vector Manufacturing market in 2024 driven by increase in prevalence of chronic disorders and increase in demand for gene and cell therapies. On February 2024, Form Bio, a cutting-edge provider of computational life sciences solutions, and Ginkgo Bioworks, which is developing the leading platform for cell programming and biosecurity, have announced a new collaboration to provide a complete and holistic solution offering for AAV gene therapy design and development. The combined offering combines the power of Ginkgo’s licensable assets, cell lines, and foundry capabilities with Form’s award-winning in silico solutions for characterization.
- Some major companies in the market report include Thermo Fisher Scientific Inc, Cytiva, F. Hoffman La Roche, Charles River Laboratories, Oxford Biomedica PLC, WuXi AppTec, Sarepta Therapeutics, Inc., AGC Biologics, Genezen, Lonza Group, Catalent Biologics, Creative Biogene, Pfizer CentreOne, and Merck KGaA.
- On October 2024, eXmoor pharma, a full-service cell and gene therapy (CGT) manufacturing partner, and Virica Biotech Inc., a leading developer of enhancers for viral vector scaling as well as cell and gene therapies, announced a new project, funded in part by a joint Canada-UK government biomanufacturing collaboration, to improve the manufacture of adeno-associated vectors (AAVs), a critical component of gene therapies. The collaboration effort will use Virica’s VSEs, tiny compounds that boost AAV productivity, and eXmoor’s scale-up process development experience to discover and deploy top candidates at commercial scale by 2025.
Unlock the key to transforming your business strategy with our Adeno Associated Virus (AAV) Vector Manufacturing insights –
Navistrat Analytics has segmented Adeno Associated Virus (AAV) vector manufacturing market based on scale of operations, method, purification, therapeutic area, and application:
- Scale of Operations Outlook (Revenue, USD Million; 2022-2032)
- Clinical
- Preclinical
- Commercial
- Method Outlook (Revenue, USD Million; 2022-2032)
- Ex Vivo
- In Vivo
- Purification Outlook (Revenue, USD Million; 2022-2032)
- Chromatography
- Density Gradient Centrifugation
- Ion Exchange Chromatography
- Affinity Chromatography
- Ultrafiltration
- Chromatography
- Therapeutic Area Outlook (Revenue, USD Million; 2022-2032)
- Genetic Disorders
- Neurological Disorders
- Infectious Diseases
- Ophthalmic Disorders
- Hematological Diseases
- Others
- Application Outlook (Revenue, USD Million; 2022-2032)
- Gene Therapy
- Vaccine
- Cell Therapy
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America